Quest Diagnostics reported a 10.2% revenue increase to $3.04 billion in Q2 2026, driven by a 10% rise in organic revenue and a 13.1% volume increase. Adjusted EPS rose to $3.12, beating analyst expectations of $2.83. Due to strong demand and successful partnerships, the company raised its full-year revenue forecast to $11.95-$12.05 billion. Barclays raised its price target for the stock from $230 to $250, signaling confidence in further upside potential.
Quest Diagnostics reported strong Q2 results with adjusted EPS of $3.12, a 19.1% increase year-over-year, beating analyst estimates of $2.83. Revenue rose 10.2% to $3.04 billion, driven by a 13.1% increase in test volume, surpassing expectations. Jef...
Quest Diagnostics reported a 10.2% increase in second-quarter revenues to $3.04 billion, driven by 10% organic growth. Adjusted diluted earnings per share rose 19.1% to $3.12, reflecting strong demand across physician, hospital, and consumer channels...
